Ultragenyx Phase 3 Aspire Trial Fails Primary Endpoint in Angelman Syndrome
RARE is trading near its 52-week low of $18.29 (21% below the low).
Summary
Ultragenyx's Phase 3 Aspire trial for apazunersen in Angelman syndrome failed its primary and key secondary endpoints. The company will evaluate the program and implement significant expense reductions.
Updates
· Reuters — Shares fell more than 40% premarket; at least five brokerages cut price targets; company announced significant expense reductions.
· Reuters — Stock is trading near its 52-week low following the failure.
Key Events · Product Development and Regulatory · RARE
-
Phase 3 Aspire Trial Misses Primary Endpoint
Apazunersen (GTX-102) failed to achieve the primary endpoint of change from baseline in Bayley-4 cognitive raw score in Angelman syndrome patients.
-
Key Secondary Endpoint Also Missed
The MDRI net response endpoint showed no differences between treated and control groups, with no efficacy signal across any of the five individual MDRI components.
-
Program Under Strategic Review
Ultragenyx will evaluate the apazunersen program and make a disposition decision, potentially discontinuing development entirely.
-
Significant Expense Reductions Planned
The company will assess operations to define and implement significant expense reductions while supporting its growing commercial business.
Analysis · RARE · Life Sciences
The Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome missed its primary endpoint on Bayley-4 cognitive raw score and the key secondary endpoint on MDRI net response. This is a major pipeline setback for a company whose recent momentum was built on the FDA approval of GENGLYCOS just two weeks ago. The company will now evaluate the program's future and implement significant expense reductions, signaling a strategic retreat from a once-promising rare disease asset. The stock is trading near its 52-week low, and this failure removes a key growth catalyst while adding restructuring uncertainty.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 50.2% of the 205 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RARE was trading at $14.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $18.29 to $39.89. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.